Eisai Co Ltd

» Auto updated continuously

Display limited to 'Eisai Co Ltd' in document titles and meta descriptions. Display In Whole Documents or use the calendar above to adjust the date setting.

 2018-09-05 10:52 

Markets Insider

Merck : China Okays LENVIMA To Treat Unresectable Hepatocellular Carcinoma...

(RTTNews) - Eisai Co., Ltd. and Merck (MRK) said that the China National Medical Products Administration or NMPA approved the kinase inhibitor LENVIMA or lenvatinib as a single agent for the treatment of patients with unresectable hepatocellular carcinoma...

 2018-08-17 21:46 

Reuters

Japan's Eisai sets price tag of about $17,000 on liver cancer drug (Aug. 16)...

Japan's Eisai Co Ltd said on Thursday it would price its cancer drug Lenvima at about $17,000 for a month's supply before discounts, after the U.S. Food and Drug Administration approved its use in patients with a common form of liver cancer....

 2018-08-17 21:46 

Reuters

[ UK ]

Japan's Eisai sets price tag of about $17,000 on liver cancer drug (Aug. 16)...

Japan's Eisai Co Ltd said on Thursday it would price its cancer drug Lenvima at about $17,000 for a month's supply before discounts, after the U.S. Food and Drug Administration approved its use in patients with a common form of liver cancer....

 2018-08-16 22:36 

Reuters

Japan's Eisai sets price tag of about $16,000 on liver cancer drug...

Japan's Eisai Co Ltd said on Thursday it would price its cancer drug Lenvima at about $16,000 for a month's supply before discounts, after the U.S. Food and Drug Administration approved its use in patients with a common form of liver cancer....

 2018-08-16 22:36 

Reuters

[ UK ]

Japan's Eisai sets price tag of about $16,000 on liver cancer drug...

Japan's Eisai Co Ltd said on Thursday it would price its cancer drug Lenvima at about $16,000 for a month's supply before discounts, after the U.S. Food and Drug Administration approved its use in patients with a common form of liver cancer....

 2018-08-16 19:35 

Channel NewsAsia

Japan's Eisai gains US approval for liver cancer treatment...

REUTERS: Japan's Eisai Co Ltd on Thursday received U.S. approval for a therapy for previously untreated patients with a common form of liver ......

 2018-08-16 19:35 

Channel NewsAsia

Japan's Eisai sets price tag of about US$16,000 on liver cancer drug...

REUTERS: Japan's Eisai Co Ltd said on Thursday it would price its cancer drug Lenvima at about US$16,000 for a month's supply before discounts, ......

 2018-08-16 19:30 

Reuters

Japan's Eisai gains U.S. approval for liver cancer treatment...

Japan's Eisai Co Ltd on Thursday received U.S. approval for a therapy for previously untreated patients with a common form of liver cancer, paving the way for multibillion dollar sales....

 2018-08-16 19:30 

Reuters

[ Health ]

Japan's Eisai gains U.S. approval for liver cancer treatment...

Japan's Eisai Co Ltd on Thursday received U.S. approval for a therapy for previously untreated patients with a common form of liver cancer, paving the way for multibillion dollar sales....

 2018-08-16 18:52 

Reuters

Japan's Eisai gains U.S. approval for liver cancer treatment...

The U.S. Food and Drug Administration on Thursday approved https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm617185.htm a therapy by Japan's Eisai Co Ltd for previously untreated patients with a common form of liver cancer....

 2018-08-16 18:52 

Reuters

[ UK ]

Japan's Eisai gains U.S. approval for liver cancer treatment...

The U.S. Food and Drug Administration on Thursday approved https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm617185.htm a therapy by Japan's Eisai Co Ltd for previously untreated patients with a common form of liver cancer....

 2018-07-10 02:20 

Markets Insider

Eisai Announces Acceptance of BAN2401 Phase II Results for Oral Presentation at the 2018 Alzheimer's Association International Conference (AAIC)...

WOODCLIFF LAKE, N.J., July 9, 2018 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announces today the results of the BAN2401 Phase II clinical study, Study 201(ClinicalTrials.gov identifier NCT01767311), will be present...

 2018-07-05 23:51 

Markets Insider

Eisai And Biogen Announce Positive Topline Results Of The Final Analysis For BAN2401 At 18 Months...

TOKYO and CAMBRIDGE, Mass., July 5, 2018 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ: BIIB) (Headquarters:...

 2018-07-02 13:01 

Markets Insider

Eisai and Purdue Pharma Announce Oral Presentation of Latest Clinical and Non-Clinical Data on Lemborexant at 43rd Annual Meeting of the Japanese Society of Sleep Research...

TOKYO and STAMFORD, Conn., July 2, 2018 /PRNewswire/ -- Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, MD "Purdue Pharma") today......

 2018-06-12 20:30 

Markets Insider

Eisai Inc. to Launch Center for Genetics Guided Dementia Discovery in Cambridge, Massachusetts...

WOODCLIFF LAKE, N.J., June 12, 2018 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it will launch the Eisai Center for Genetics Guided Dementia Discovery, which will harness the power of human genetics t...

 2018-06-05 21:01 

Markets Insider

Positive New Data on Investigational Lemborexant Presented at 32nd Annual SLEEP Meeting...

TOKYO and STAMFORD, Conn., June 5, 2018 /PRNewswire/ -- Eisai Co., Ltd. (CEO: Haruo......

 2018-05-01 10:51 

Reuters

Merck posts 52.5 percent fall in quarterly profit...

Drugmaker Merck & Co posted a 52.5percent fall in first-quarter profit on Tuesday, hurt by heftycharge related to its collaboration with Eisai Co Ltd....

 2018-05-01 10:51 

Reuters

[ UK ]

Merck posts 52.5 percent fall in quarterly profit...

Drugmaker Merck & Co posted a 52.5 percent fall in first-quarter profit on Tuesday, hurt by hefty charge related to its collaboration with Eisai Co Ltd....

 2018-03-08 07:32 

Reuters

[ Health ]

Eisai clinches Merck deal to develop and sell cancer drug, shares soar...

NEW YORK/TOKYO (Reuters) - Merck & Co Inc and Japan's Eisai Co Ltd have signed a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already approved in dozens of countries for two uses....

 2018-03-08 07:32 

Reuters

Eisai clinches Merck deal to develop and sell cancer drug, shares soar...

Merck & Co Inc and Japan's Eisai Co Ltd have signed a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already approved in dozens of countries for two uses....

 2018-03-08 07:32 

Reuters

[ UK ]

Eisai clinches Merck deal to develop and sell cancer drug, shares soar...

Merck & Co Inc and Japan's Eisai Co Ltd have signed a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already approved in dozens of countries for two uses....

 2018-03-08 02:07 

Reuters

[ Health ]

Merck, Eisai in deal to further develop, sell Eisai cancer drug...

NEW YORK (Reuters) - Merck & Co Inc and Japan's Eisai Co Ltd on Wednesday announced a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already approved in dozens of countries for two uses....

 2018-03-08 02:07 

Reuters

Merck, Eisai in deal to further develop, sell Eisai cancer drug...

Merck & Co Inc and Japan's Eisai Co Ltd on Wednesday announced a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already approved in dozens of countries for two uses....

 2018-03-07 22:37 

Reuters

BRIEF-Eisai Co, Merck Announce Oncology Collaboration For Lenvima...

Eisai Co Ltd:...

 2018-03-07 22:37 

Reuters

[ UK ]

BRIEF-Eisai Co, Merck Announce Oncology Collaboration For Lenvima...

Eisai Co Ltd:...

 2018-03-07 22:18 

Reuters

[ Health ]

Merck, Eisai sign deal to further develop, sell Eisai cancer drug...

(Reuters) - Merck & Co and Japan's Eisai Co Ltd on Wednesday announced a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already approved in many countries for two uses....

 2018-03-07 22:18 

Reuters

Merck, Eisai sign deal to further develop, sell Eisai cancer drug...

Merck & Co Inc and Japan's Eisai Co Ltd on Wednesday announced a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already approved in dozens of countries for two uses....

 2018-01-10 14:35 

Reuters

BRIEF-Morphotek Announces FDA Acceptance Of IND For Cancer Treatment...

Eisai Co Ltd:...

 2018-01-09 12:02 

Reuters

BRIEF-Eisai, Merck Receive Breakthrough Therapy Designation From FDA For Lenvima, Keytruda...

Eisai Co Ltd:...

Page 1 of 1

  • Need an account?  
    or